Singh Balraj, Ayad Sarah, Kaur Parminder, Kumar Vinod, Gupta Sachin, Maroules Michael
Department of Hematology & Oncology, Saint Joseph's University Medical Center, Paterson, NJ, USA.
Department of Cardiology, Saint Joseph's University Medical Center, Paterson, NJ, USA.
Eur J Case Rep Intern Med. 2021 Jan 12;8(1):002233. doi: 10.12890/2021_002233. eCollection 2021.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), has caused a global health crisis. COVID-19 can have a multifaceted presentation, and a wide range of complications and outcomes may emerge based on the severity and comorbidities of the infected patient. We report the case of a 42-year-old man with a history of chronic myeloid leukaemia (CML) on dasatinib (in major molecular response) who was diagnosed with COVID-19 and developed pancytopenia. Our case report and review of available publications add to the limited literature available regarding COVID-19 in CML.
Our case report and review of the literature highlight the multifaceted response in chronic myeloid leukaemia (CML) patients to COVID-19 (respiratory symptoms, pancytopenia, severe haemolytic anaemia and haemophagocytic lymphohistiocytosis, disseminated erythematous papular skin rash).The rates of intensive care unit admission and mechanical ventilation support, and lengths of hospital stay were lower in COVID-19 patients with CML receiving tyrosine kinase inhibitors (TKI) compared with an age, gender and comorbidity-matched control group.Our case report and review of the literature suggest a possible protective effect of TKI therapy against COVID-19 in patients with CML.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2），即引起2019冠状病毒病（COVID-19）的病毒，已引发全球健康危机。COVID-19的表现可能是多方面的，根据感染患者的严重程度和合并症，可能会出现各种各样的并发症和后果。我们报告了一例42岁男性病例，该患者有慢性髓性白血病（CML）病史，正在服用达沙替尼（处于主要分子反应阶段），被诊断为COVID-19并出现全血细胞减少。我们的病例报告以及对现有文献的回顾，为关于CML患者中COVID-19的有限文献增添了内容。
我们的病例报告和文献回顾突出了慢性髓性白血病（CML）患者对COVID-19的多方面反应（呼吸道症状、全血细胞减少、严重溶血性贫血和噬血细胞性淋巴组织细胞增生症、弥漫性红斑丘疹皮疹）。与年龄、性别和合并症匹配的对照组相比，接受酪氨酸激酶抑制剂（TKI）治疗的CML合并COVID-19患者的重症监护病房入住率和机械通气支持率以及住院时间较低。我们的病例报告和文献回顾表明，TKI治疗对CML患者的COVID-19可能具有保护作用。
